Skip to main content
. Author manuscript; available in PMC: 2009 Jun 29.
Published in final edited form as: J Dermatol Sci. 2007 Aug 8;48(2):87–101. doi: 10.1016/j.jdermsci.2007.06.006

Figure 1. Clinical perspective of skin lesions on a psoriatic patient before and after adalimumab therapy.

Figure 1

Compared to adjacent symptomless (PN) skin, designated by red circle, the baseline appearance for untreated psoriatic plaques (PP skin) revealed well demarcated, erythematous, and scaly lesions (a). On day 7 after delivery of a single loading dose of adalimumab (80 mg, subcutaneous) the lesional skin is characterized by reduced thickness, erythema, and scaling (b; the sutures represent biopsy sites for PN and PP skin). On day 28 after continuation of adalimumab therapy, the target plaque is almost completely resolved with only slight residual erythema; a clinical trend continued on day 84 of therapy (c, d). Note the resolution of the inflammation and tissue remodeling of PP skin by adalimumab was not accompanied by any scar formation.